DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis
Sponsored by Alnylam Pharmaceuticals
About this trial
Last updated 9 years ago
Study ID
ALN-TTR-NT-002
Status
Completed
Type
Observational
Placebo
No
Accepting
18+ Years
All
Not accepting
Healthy Volunteers
Trial Timing
Ended 9 years ago
What is this trial about?
The purpose of this study is to characterize the frequency of TTR mutations in subjects
suspected of having cardiac amyloidosis
What are the participation requirements?
Inclusion Criteria
- Males or females >18 years old
- History of evidence suggestive of cardiac amyloidosis
- Subject is willing and able to comply with protocol required assessments and provide written informed consent
Exclusion Criteria
- Known diagnosis of primary (AL) amyloidosis
- Known diagnosis of hereditary cardiomyopathy or cardiomyopathy due to aortic stenosis
- Patient is currently pregnant
For more information, view the full study details:
NCT02252653